6-((4-(Dimethylamino)-3-hydroxy-6-methyloxan-2-yl)oxy)-14-ethyl-7,12,13-trihydroxy-4-((5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl)oxy)-3,5,7,9,11,13-hexamethyl-1-oxacyclotetradecane-2,10-dione

Details

• Internal ID: bceaebcc-7c2c-44e3-b408-bd2fc7063750
• Taxonomy: Organic oxygen compounds > Organooxygen compounds > Carbohydrates and carbohydrate conjugates > Aminosaccharides > Aminoglycosides
• IUPAC Name: 6-[4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-(5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl)oxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione
• InChI: InChI=1S/C37H67NO13/c1-14-25-37(10,45)30(41)20(4)27(39)18(2)16-35(8,44)32(51-34-28(40)24(38(11)12)15-19(3)47-34)21(5)29(22(6)33(43)49-25)50-26-17-36(9,46-13)31(42)23(7)48-26/h18-26,28-32,34,40-42,44-45H,14-17H2,1-13H3
• InChI Key: ULGZDMOVFRHVEP-UHFFFAOYSA-N
• Popularity: 4 references in papers

Physical and Chemical Properties

• Molecular Formula: C₃₇H₆₇NO₁₃
• Molecular Weight: 733.90 g/mol
• Exact Mass: 733.46124119 g/mol
• Topological Polar Surface Area (TPSA): 194.00 Ų
• XlogP: 2.70
• Atomic LogP (AlogP): 1.79
• H-Bond Acceptor: 14
• H-Bond Donor: 5
• Rotatable Bonds: 7

Synonyms

• 6-((4-(Dimethylamino)-3-hydroxy-6-methyloxan-2-yl)oxy)-14-ethyl-7,12,13-trihydroxy-4-((5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl)oxy)-3,5,7,9,11,13-hexamethyl-1-oxacyclotetradecane-2,10-dione
• 6-{[4-(Dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy}-14-ethyl-7,12,13-trihydroxy-4-[(5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl)oxy]-3,5,7,9,11,13-hexamethyl-1-oxacyclotetradecane-2,10-dione
• RefChem:1073650
• DTXCID80196652
• Erythromid
• Abboticin
• Erycinum
• Ilocaps
• Erycin
• Kesso-Mycin
• Taimoxin-F
• Erythrocin
• Pantomicina
• ERYTHROMYCIN A DIHYDRATE
• erythro
• Ermycin
• Erycen
• Erytab
• Inderm
• Aknin
• Theramycin Z
• Ak-Mycin
• adecane-2,10-dione (non-preferred name)
• C37H67NO13
• IndermRetcin
• Erythromycin D3
• 6-{[4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy}-14-ethyl-7,12,13-trihydroxy-4-[(5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl)oxy]-3,5,7,9,11,13-hexamethyloxacyclotetr
• 959119-26-7
• Erythromycin, sodium salt
• CHEMBL1671887
• component of Drixin (Salt/Mix)
• SCHEMBL15263177
• BDBM86313
• component of T-stat (Salt/Mix)
• Erythromycin sodium lauryl sulfate
• ULGZDMOVFRHVEP-UHFFFAOYSA-N
• HMS5079F04
• BBL028236
• NSC_12560
• SBB057401
• STK249736
• thyl-6-oxacyclotetradecane-1,7-dione
• AKOS005423023
• 6-[4-(dimethylamino)-3-hydroxy-6-methyl-tetrahydropyran-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-(5-hydroxy-4-methoxy-4,6-dimethyl-tetrahydropyran-2-yl)oxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione
• CAS_114-07-8
• FE176617
• DB-041196
• NS00076487
• component of Benzedrex nasal spray (Salt/Mix)
• (3R*,4S*,5S*,6R*,7R*,9R*,11R*,12R*,13S*,14R*)-4-[(2,6-Dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribo-hexopyranosyl)oxy]-14-ethyl-7,12,13-trihydroxy-3,5,7,9,11,13-hexamethyl-6-[[3,4,6-trideoxy-3-(dimethylamino)-.beta.-D-xylo-hexopyranosyl]oxy]oxacyclotetradecane-2,10-dione
• [3R-(3R*,4S*,5S*,6R*,7R*,9R*,11R*,12R*,13S*,14R*)]-4-[(2,6-Dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribo-hexopyranosyl)oxy]-14-ethyl-7,12,13-trihydroxy-3,5,7,9,11,13-hexamethyl-6-[[3,4,6-trideoxy-3-(dimethylamino)-.beta.-D-xylo-hexopyranosyl]oxy]oxacyclotetradecane-2,10-dione
• 11-[4-(dimethylamino)-3-hydroxy-6-methyl(2H-3,4,5,6-tetrahydropyran-2-yl)oxy]- 5-ethyl-3,4,12-trihydroxy-9-(5-hydroxy-4-methoxy-4,6-dimethyl(2H-3,4,5,6-tetra hydropyran-2-yl)oxy)-2,4,8,10,12,14-hexame
• 6-(4-dimethylamino-3-hydroxy-6-methyl-oxan-2-yl)oxy-14-ethyl-7,12,13-trihydroxy-4-(5-hydroxy-4-methoxy-4,6 dimethyl-oxan-2-yl)oxy-3,5,7,9,11,13-hexamethyl-1 oxacyclotetradecane-2,10-dione
• Oxacyclotetradecane-2, 4-[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribo-hexopyranosyl)oxy]-14-ethyl-7,12,13-trihydroxy-3,5,7,9,11,13-hexamethyl-6-[[3,4,6-trideoxy-3-(dimethylamino)-.beta.-D-xylo-hexopyranosyl]oxy]-, [2R-(2R*,3S*,4S*,5R*,6R*,8R*,10R*,11R*,12S*,13S*)]-
• Oxacyclotetradecane-2,10-dione, 4-[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribo-hexopyranosyl)oxy]-14-ethyl-7,12,13-trihydroxy-3,5,7,9,11,13-hexamethyl-6-[[3,4,6-trideoxy-3-(dimethylamino)-.beta.-D-xylo-hexopyranosyl]oxy]-, [3R-(3R*,4S*,5S*,6R*,7R*,9R*,11R*,12R*,13S*,14R*)]-
• Pentadecanoic acid, 3-[(2,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribo-hexopyranosyl)oxy]-6,11,12,13-tetrahydroxy-2,4,6,8,10,12-hexamethyl-9-oxo-5-[[3,4,6-trideoxy-3-(dimethylamino)-.beta.-D-xylo-hexopyranosyl]oxy]-, .mu.-lactone, [2R-(2R*,3S*,4S*,5R*,6R*,8R*,10R*,11R*,12S*,13S*)]-
• Pentadecanoic acid,6-dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribo-hexopyranosyl)oxy]-6,11,12,13-tetrahydroxy-2,4,6,8,10,12-hexamethyl-9-oxo-5-[[3,4,6-trideoxy-3-(dimethylamino)-.beta.-D-xylo-hexopyranosyl]oxy]-, .mu.-lactone, [2R-(2R*,3S*,4S*,5R*,6R*,8R*,10R*,11R*,12S*,13S*)]-
• WLN: T-14-VO GVTJ C2 DQ D1 EQ F1 H1 JQ J1 L1 N1 KO-BT6OTJ CQ DN1 & 1 F1 & MO-FT6OTJ B1 CQ DO1 D1

2D Structure

ADMET Properties (via admetSAR 2)

Target	Value	Probability (raw)	Probability (%)
Human Intestinal Absorption	+	0.7859	78.59%
Caco-2	-	0.9372	93.72%
Blood Brain Barrier	-	1.0000	100.00%
Human oral bioavailability	-	0.8000	80.00%
Subcellular localzation	Lysosomes	0.6348	63.48%
OATP2B1 inhibitior	-	1.0000	100.00%
OATP1B1 inhibitior	+	0.9413	94.13%
OATP1B3 inhibitior	+	0.9480	94.80%
MATE1 inhibitior	-	1.0000	100.00%
OCT2 inhibitior	-	1.0000	100.00%
BSEP inhibitior	-	0.8665	86.65%
P-glycoprotein inhibitior	+	0.7128	71.28%
P-glycoprotein substrate	+	0.9225	92.25%
CYP3A4 substrate	+	0.7340	73.40%
CYP2C9 substrate	-	1.0000	100.00%
CYP2D6 substrate	-	0.8938	89.38%
CYP3A4 inhibition	-	0.5744	57.44%
CYP2C9 inhibition	-	0.9070	90.70%
CYP2C19 inhibition	-	0.9074	90.74%
CYP2D6 inhibition	-	0.9230	92.30%
CYP1A2 inhibition	-	0.9045	90.45%
CYP2C8 inhibition	-	0.9882	98.82%
CYP inhibitory promiscuity	-	0.9391	93.91%
UGT catelyzed	-	0.5000	50.00%
Carcinogenicity (binary)	-	0.9700	97.00%
Carcinogenicity (trinary)	Non-required	0.5441	54.41%
Eye corrosion	-	0.9883	98.83%
Eye irritation	-	0.9132	91.32%
Skin irritation	-	0.7819	78.19%
Skin corrosion	-	0.9180	91.80%
Ames mutagenesis	-	0.9700	97.00%
Human Ether-a-go-go-Related Gene inhibition	-	0.7450	74.50%
Micronuclear	+	0.5700	57.00%
Hepatotoxicity	+	1.0000	100.00%
skin sensitisation	-	0.9376	93.76%
Respiratory toxicity	+	0.9778	97.78%
Reproductive toxicity	+	0.8333	83.33%
Mitochondrial toxicity	+	0.9750	97.50%
Nephrotoxicity	-	0.8450	84.50%
Acute Oral Toxicity (c)	III	0.7984	79.84%
Estrogen receptor binding	-	0.7769	77.69%
Androgen receptor binding	-	0.6632	66.32%
Thyroid receptor binding	-	0.7874	78.74%
Glucocorticoid receptor binding	+	0.7259	72.59%
Aromatase binding	+	0.6356	63.56%
PPAR gamma	+	0.7056	70.56%
Honey bee toxicity	-	0.5745	57.45%
Biodegradation	-	0.9250	92.50%
Crustacea aquatic toxicity	+	0.6200	62.00%
Fish aquatic toxicity	-	0.4056	40.56%

Targets

Proven Targets:

CHEMBL ID	UniProt ID	Name	Min activity	Assay type	Source
CHEMBL240	Q12809	HERG	39 nM	IC50	via Super-PRED
CHEMBL1293235	P02545	Prelamin-A/C	5.6 nM	Potency	via Super-PRED

Predicted Targets (via Super-PRED):

CHEMBL ID	UniProt ID	Name	Probability	Model accuracy
CHEMBL3251	P19838	Nuclear factor NF-kappa-B p105 subunit	98.28%	96.09%
CHEMBL253	P34972	Cannabinoid CB2 receptor	95.37%	97.25%
CHEMBL5619	P27695	DNA-(apurinic or apyrimidinic site) lyase	94.29%	91.11%
CHEMBL2581	P07339	Cathepsin D	94.16%	98.95%
CHEMBL3137262	O60341	LSD1/CoREST complex	92.44%	97.09%
CHEMBL4261	Q16665	Hypoxia-inducible factor 1 alpha	91.38%	85.14%
CHEMBL4478	Q00975	Voltage-gated N-type calcium channel alpha-1B subunit	87.52%	97.14%
CHEMBL1293249	Q13887	Kruppel-like factor 5	87.47%	86.33%
CHEMBL3880	P07900	Heat shock protein HSP 90-alpha	86.40%	96.21%
CHEMBL2069156	Q14145	Kelch-like ECH-associated protein 1	86.11%	82.38%
CHEMBL241	Q14432	Phosphodiesterase 3A	86.05%	92.94%
CHEMBL3108638	O15164	Transcription intermediary factor 1-alpha	86.05%	95.56%
CHEMBL2996	Q05655	Protein kinase C delta	85.68%	97.79%
CHEMBL5608	Q16288	NT-3 growth factor receptor	84.74%	95.89%
CHEMBL1994	P08235	Mineralocorticoid receptor	84.59%	100.00%
CHEMBL2635	P51452	Dual specificity protein phosphatase 3	84.12%	94.00%
CHEMBL2007	P16234	Platelet-derived growth factor receptor alpha	84.10%	91.07%
CHEMBL4303	P08238	Heat shock protein HSP 90-beta	84.05%	96.77%
CHEMBL233	P35372	Mu opioid receptor	83.92%	97.93%
CHEMBL1806	P11388	DNA topoisomerase II alpha	83.40%	89.00%
CHEMBL3392948	Q9NP59	Solute carrier family 40 member 1	83.32%	95.00%
CHEMBL255	P29275	Adenosine A2b receptor	81.02%	98.59%
CHEMBL2111367	P27986	PI3-kinase p110-alpha/p85-alpha	80.91%	94.33%

Plants that contains it

There are no matching plants.

Cross-Links

• PubChem: 3255
• LOTUS: LTS0172645
• wikiData: Q105275120